Subvisible Particle Content, Formulation, and Dose of an Erythropoietin Peptide Mimetic Product Are Associated With Severe Adverse Postmarketing Events
Author:
Joseph Kotarek,Christine Stuart,Silvia H. De Paoli,Jan Simak,Tsai-Lien Lin,Yamei Gao,Mikhail Ovanesov,Yideng Liang,Dorothy Scott,Janice Brown,Yun Bai,Dean D. Metcalfe,Ewa Marszal,Jack A. Ragheb
Publication:
Journal of Pharmaceutical Sciences
Copyright © 2016 Published by Elsevier Inc.